Breaking News

West Completes Initial SmartDose Tech Platform Study

November 7, 2013

Container system aims to meet the needs of modern biologics

West Pharmaceutical Services has completed a preliminary study of its SmartDose technology platform, which incorporates a Daikyo Crystal Zenith (CZ) cartridge. The study evaluated self-application, safety, performance, and tolerability of SmartDose 2.5 using saline in healthy subjects.
 
The Daikyo CZ cartridge with the Flurotec film coated piston and seal comprise a container system specifically designed for most modern biologic medications. West and Daikyo Seiko have developed CZ primary container systems in an effort to reduce interaction with biologics, as well as the added benefits of break resistance, higher quality standards, dimensional tolerance, and functionality associated with polymer systems.
 
"We believe our efforts to develop the SmartDose technology platform system are important, because we see an unmet need for high-volume subcutaneous delivery of viscous or sensitive drug products, which may require longer injection times," said Paul Norton, vice president of Self-Injection Systems at West. "Daikyo Crystal Zenith has a long history of use as a primary drug container, and many of our customers find Daikyo Crystal Zenith an attractive option based on quality, stability and performance considerations. The flexibility of CZ allows it to be optimized for use with the SmartDose platform and makes it possible to utilize these technologies for the next generation of self-administered protein-based drugs."

blog comments powered by Disqus
  • Cryogenic Cold Chain Risk Mitigation

    Cryogenic Cold Chain Risk Mitigation

    Kristin Brooks, Contract Pharma||November 13, 2015
    Mark Sawicki of Cryoport explains the requirements, challenges, and regulatory aspects around cryogenic logistics

  • A Biologic Innovator

    A Biologic Innovator's Pursuit to Uphold Patents

    Kristin Brooks, Contract Pharma||October 12, 2015
    Amgen v. Sandoz biosimilars litigation could impact the industry for years to come

  • 2015 Contracting & Outsourcing Wrap-up

    2015 Contracting & Outsourcing Wrap-up

    Kristin Brooks, Contract Pharma||September 30, 2015
    A huge success, with another year of record attendance, sold-out exhibit hall, and a great line up of informative sessions

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • CMOs: A Flexibility Alternative

    CMOs: A Flexibility Alternative

    Philip K. Burns, CRO-Consulting||January 28, 2016
    A look at how to include CMOs as an option to improve overall flexibility

  • Cold-Chain Logistics & The Central Lab

    Kristin Brooks, Associate Editor||January 28, 2016
    Eric Hayashi of LabConnect discusses safety measures to ensure sample integrity